The new scanner offers accurate, reproducible quantification in molecular imaging, for results that redefine clinical decision-making

Chicago - At the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 27 to December 2, Siemens Healthcare (Booth #822, East Building/Lakeside Center at McCormick Place, Hall D) introduced the next-generation Biograph mCT, a positron emission tomography/computed tomography (PET•CT) scanner that enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). Technological innovations and intelligent software solutions within the new PET•CT result in quantitative assessments that are accurate and consistent. With the new Biograph mCT, Siemens presents another paradigm in PET•CT, further strengthening the company's innovative power and competitiveness - a goal of its recently introduced global initiative, Agenda 2013.

"By bringing accuracy and reproducibility to quantification in PET, we can more precisely characterize cancer lesions, allowing for better staging and monitoring of the change in activity over time for more accurate assessment of treatment response," said Jerry Froelich, MD, FACR, Loken Professor of Radiological Sciences and head of molecular imaging and nuclear medicine at the University of Minnesota, Minneapolis. "In cardiology, being able to measure absolute myocardial blood flow allows for accurate assessment of multi-vessel disease. In neurology, the potential is huge. The ability to noninvasively assess the brain can improve the diagnosis and therefore management of patients presenting signs of Alzheimer's disease."
Siemens implemented these clinical requirements in the new Biograph mCT, which supports physicians in treating many oncological, cardiological and neurological diseases - not only through earlier, more exact diagnosis, but also in therapy planning and precise monitoring of disease progression. The additional information provided enables physicians to make decisions with high certainty and initiate more patient-tailored therapies.

The level of measurement and quantification offered by the new Biograph mCT has special significance for the diagnosis of neurodegenerative diseases such as dementia.

With the latest Biograph mCT and potential new PET biomarkers, reliable imaging of beta-amyloid plaque in the brain may be possible, providing additional information to aid in the diagnosis of dementia,1 potentially slowing disease progression through earlier care. The most frequently diagnosed form of dementia is Alzheimer's disease, which currently affects an estimated 35.6 million people worldwide. As many as 115.4 million patients could have the disease by 2050.2

More HCB News